New York, May 28, 2026, 06:06 EDT
- Sight Sciences ended Wednesday at $4.87, slipping 2.4%. The stock showed no move in premarket quotes ahead of Thursday’s regular U.S. open.
- The stock is testing new levels after the May 26 Stifel ophthalmology forum and the company’s recent bump to its 2026 revenue guidance.
- Investors are focused on OMNI glaucoma demand, TearCare reimbursement, and the risk from the Alcon patent award appeal.
Sight Sciences, Inc. was flat in premarket trading, holding just above Wednesday’s close after losing 2.4% the day before. SGHT was quoted at $4.87 on Google Finance, unchanged ahead of the bell, following a Wednesday session that swung between $4.82 and $5.08. The market cap sits around $265 million. Investors are weighing whether the company’s 2026 growth reset will hold up.
Timing is in play. Sight Sciences showed up at the Stifel 2026 Virtual Ophthalmology Forum on May 26, right after the post-Memorial Day holiday market closure—Nasdaq U.S. markets were shut May 25. The company’s investor page puts the Stifel slot at noon EDT, with management’s glaucoma and dry-eye updates going out ahead of Thursday’s trading.
Management at the Stifel event talked about the interventional glaucoma market still growing, reimbursement efforts for TearCare and the expected launch of OMNI Ultra, a new product due later this year, according to a Quartr summary. The summary noted that expansion in dry eye market access could add upside.
Sight Sciences used the May 6 quarter as its financial base. The company posted Q1 revenue of $19.7 million, which is up 13% from a year back. Sight Sciences also increased its 2026 revenue range to $83 million to $89 million, from the old range of $82 million to $88 million. Net loss for the quarter was $13.0 million, or 24 cents a share. As of March, the company had $85.0 million in cash and $40.0 million in long-term debt. CEO Paul Badawi said it was “a strong start to 2026.” Sight Sciences
Sight Sciences isn’t delivering a straightforward profit yet. CFO Jim Rodberg told investors the company sees a way to “cash flow breakeven” without more equity, but COO Alison Bauerlein said TearCare accounts “are not anywhere close to a steady state yet,” leaving room for higher usage in reimbursed markets. The Motley Fool
OMNI continues as Sight Sciences’ main business. Glaucoma sales brought in $18.3 million, up 7% in Q1. Interventional dry-eye revenue shot up 244% to $1.4 million. MIGS, or microinvasive glaucoma surgery, involves small incisions to lower eye pressure with less tissue damage than traditional surgery.
Dry eye is still the smaller business, though it’s the main swing factor. Sight Sciences has connected its TearCare launch to decisions by the regional Medicare Administrative Contractors, or MACs. These groups process Medicare claims and set payment rules in their areas. After two MACs set fee schedules for the TearCare code, Sight Sciences said SmartLids sales picked up.
Competition is stiff. Alcon is still the main rival, tied to Sight Sciences’ patent fight on the Hydrus Microstent. Glaukos, which also targets glaucoma, was at the Stifel ophthalmology event on May 26. Glaukos claims it originated MIGS to replace older glaucoma treatments, with the company saying investors are watching reimbursement, adoption, and product differences in the field.
The risk for Sight Sciences stands out. The 10-Q notes the Alcon judgment can be appealed. Two patent reexams are still open. The company also flagged reimbursement, competition, tariffs and volatility as issues. Rodberg said, “no cash has been received to date” from the Alcon case. If the court result weakens or payers grow slower or procedures dip, growth could take a hit. Sight Sciences
SGHT trades as a small-cap execution name for now. What happens next looks tied less to any single conference and more to second-quarter numbers confirming if OMNI’s growth story holds up and whether TearCare starts picking up traction outside of its first reimbursed markets.
